CoChat

Platelet-derived serotonin links vascular disease and tissue fibrosis

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Vascular damage and platelet activation are associated with tissue remodeling in diseases such as systemic sclerosis, but the molecular mechanisms underlying this association have not been identified. In this study, we show that serotonin (5-hydroxytryptamine [5-HT]) stored in platelets strongly induces extracellular matrix synthesis in interstitial fibroblasts via activation of 5-HT2B receptors (5-HT2B) in a transforming growth factor β (TGF-β)–dependent manner. Dermal fibrosis was reduced in 5-HT2B−/− mice using both inducible and genetic models of fibrosis. Pharmacologic inactivation of 5-HT2B also effectively prevented the onset of experimental fibrosis and ameliorated established fibrosis. Moreover, inhibition of platelet activation prevented fibrosis in different models of skin fibrosis. Consistently, mice deficient for TPH1, the rate-limiting enzyme for 5-HT production outside the central nervous system, showed reduced experimental skin fibrosis. These findings suggest that 5-HT/5-HT2B signaling links vascular damage and platelet activation to tissue remodeling and identify 5-HT2B as a novel therapeutic target to treat fibrotic diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20101629

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. 5-HT stimulates the production of extracellular matrix in dermal fibroblasts. (A–C) mRNA levels of col 1a1 (A), col 1a2 (B), and fibronectin-1 (C) after stimulation of SSc and healthy dermal fibroblasts with 5-HT. (D) The release of collagen protein from dermal fibroblasts upon 5-HT stimulation (n = 5 each). *, P < 0.05 compared with controls. The experiment was performed in two independent series. Error bars indicate SE.
Figure 1. 5-HT stimulates the production of extracellular matrix in dermal fibroblasts. (A–C) mRNA levels of col 1a1 (A), col 1a2 (B), and fibronectin-1 (C) after stimulation of SSc and healthy dermal fibroblasts with 5-HT. (D) The release of collagen protein from dermal fibroblasts upon 5-HT stimulation (n = 5 each). *, P < 0.05 compared with controls. The experiment was performed in two independent series. Error bars indicate SE.CC BY-NC-SA · PubMed Central
Figure 2. Inhibition of 5-HT2B but not of 5-HT1B or 5-HT2A reduces the 5-HT–induced expression of extracellular matrix proteins. (A–D) Inhibition of 5-HT receptors by selective inhibitors at concentrations of 0.1 and 1.0 µM. mRNA levels of col 1a1 (A), col 1a2 (B), and fibronectin-1 (C) and release of collagen protein (D) after incubation with the 5-HT1B antagonist SB 224289, ketanserin (5-HT2A), and the 5-HT2B inhibitor SB 204741 (n = 7 each, two independent series). *, P < 0.05 compared with 5-HT–stimulated cells. (E–H) Knockdown of 5-HT2B by siRNA. (E) Expression levels of 5-HT2B protein after nucleofection with 5-HT2B and mock siRNA. (F–H) mRNA levels of col 1a1 (F), col 1a2 (G), and fibronectin-1 (H) after knockdown of 5-HT2B by siRNA in 5-HT–stimulated SSc dermal fibroblasts compared with mock-transfected cells (n = 5, two independent series). Error bars indicate SE.
Figure 2. Inhibition of 5-HT2B but not of 5-HT1B or 5-HT2A reduces the 5-HT–induced expression of extracellular matrix proteins. (A–D) Inhibition of 5-HT receptors by selective inhibitors at concentrations of 0.1 and 1.0 µM. mRNA levels of col 1a1 (A), col 1a2 (B), and fibronectin-1 (C) and release of collagen protein (D) after incubation with the 5-HT1B antagonist SB 224289, ketanserin (5-HT2A), and the 5-HT2B inhibitor SB 204741 (n = 7 each, two independent series). *, P < 0.05 compared with 5-HT–stimulated cells. (E–H) Knockdown of 5-HT2B by siRNA. (E) Expression levels of 5-HT2B protein after nucleofection with 5-HT2B and mock siRNA. (F–H) mRNA levels of col 1a1 (F), col 1a2 (G), and fibronectin-1 (H) after knockdown of 5-HT2B by siRNA in 5-HT–stimulated SSc dermal fibroblasts compared with mock-transfected cells (n = 5, two independent series). Error bars indicate SE.CC BY-NC-SA · PubMed Central
Figure 3. 5-HT2B is overexpressed in patients with SSc. (A) 5-HT2B was detectable by immunohistochemistry in fibroblasts, keratinocytes, and microvessels of SSc patients and controls. Two representative tissue sections and an isotype control are shown. (B) 5-HT2B expression in SM22-α–negative and α-SMA–positive myofibroblasts. A representative skin section of an SSc patient is shown. SM22-α as specific marker for vascular smooth muscle cells was stained with DAB, the myofibroblast marker α-SMA with Alexa Flour 594 (red), and 5-HT2B with Alexa Flour 488 (green; n = 8 each). The stainings were performed in three independent series. Bars: (A and B [top]) 50 µm; (B, bottom) 10 µm.
Figure 3. 5-HT2B is overexpressed in patients with SSc. (A) 5-HT2B was detectable by immunohistochemistry in fibroblasts, keratinocytes, and microvessels of SSc patients and controls. Two representative tissue sections and an isotype control are shown. (B) 5-HT2B expression in SM22-α–negative and α-SMA–positive myofibroblasts. A representative skin section of an SSc patient is shown. SM22-α as specific marker for vascular smooth muscle cells was stained with DAB, the myofibroblast marker α-SMA with Alexa Flour 594 (red), and 5-HT2B with Alexa Flour 488 (green; n = 8 each). The stainings were performed in three independent series. Bars: (A and B [top]) 50 µm; (B, bottom) 10 µm.CC BY-NC-SA · PubMed Central
Figure 4. 5-HT exerts its profibrotic effects via activation of TGF-β/Smad-dependent pathways. (A and B) mRNA levels of TGF-β1 (A) and PAI-1 (B) in 5-HT–stimulated SSc fibroblasts (n = 9, three independent series). (C) Nuclear accumulation of p-Smad3 protein complexes after 12 and 24 h of stimulation with 1 µM 5-HT (n = 3). (D–F) mRNA expression of col 1a1 (D), col 1a2 (E), and fibronectin-1 (F) upon incubation with 500 ng/ml of neutralizing antibodies (Ab) against TGF-β1 in 5-HT–stimulated SSc fibroblasts (n = 5 each, two independent series). *, P < 0.05 compared with 5-HT–stimulated (D–F) or nonstimulated (A and B) controls. Error bars indicate SE.
Figure 4. 5-HT exerts its profibrotic effects via activation of TGF-β/Smad-dependent pathways. (A and B) mRNA levels of TGF-β1 (A) and PAI-1 (B) in 5-HT–stimulated SSc fibroblasts (n = 9, three independent series). (C) Nuclear accumulation of p-Smad3 protein complexes after 12 and 24 h of stimulation with 1 µM 5-HT (n = 3). (D–F) mRNA expression of col 1a1 (D), col 1a2 (E), and fibronectin-1 (F) upon incubation with 500 ng/ml of neutralizing antibodies (Ab) against TGF-β1 in 5-HT–stimulated SSc fibroblasts (n = 5 each, two independent series). *, P < 0.05 compared with 5-HT–stimulated (D–F) or nonstimulated (A and B) controls. Error bars indicate SE.CC BY-NC-SA · PubMed Central
Figure 5. Inhibition of 5-HT signaling by the 5-HT2 inhibitors terguride, cyproheptadine, and SB 204741 prevents accumulation of extracellular matrix in experimental dermal fibrosis. (A) Representative trichrome-stained tissue sections are shown: control mice injected intracutaneously with NaCl (n = 10), bleomycin-challenged mice without antifibrotic treatment (n = 10), mice receiving bleomycin and terguride at a concentration of 0.2 mg/kg/bid (n = 8), mice treated with bleomycin and terguride at a concentration of 0.6 mg/kg/bid (n = 8), mice treated with bleomycin and cyproheptadine at a concentration of 10 mg/kg/d (n = 6), mice treated with bleomycin and SB 204741 at a concentration of 5 mg/kg/d (n = 6), and mice treated with bleomycin and imatinib at a concentration of 50 mg/kg/d (n = 6). Bars, 100 µm. (B) Dermal thickening upon challenge with bleomycin and treatment with terguride, cyproheptadine, SB 204741, or imatinib. (C) Collagen accumulation in lesional skin as analyzed with the SirCol collagen assay. (D) Myofibroblast counts after treatment of bleomycin-challenged mice with terguride, cyproheptadine, SB 204741, or imatinib. *, P < 0.05 compared with bleomycin-treated mice without antifibrotic treatment. The experiment was performed in two independent series. Error bars indicate SE.
Figure 5. Inhibition of 5-HT signaling by the 5-HT2 inhibitors terguride, cyproheptadine, and SB 204741 prevents accumulation of extracellular matrix in experimental dermal fibrosis. (A) Representative trichrome-stained tissue sections are shown: control mice injected intracutaneously with NaCl (n = 10), bleomycin-challenged mice without antifibrotic treatment (n = 10), mice receiving bleomycin and terguride at a concentration of 0.2 mg/kg/bid (n = 8), mice treated with bleomycin and terguride at a concentration of 0.6 mg/kg/bid (n = 8), mice treated with bleomycin and cyproheptadine at a concentration of 10 mg/kg/d (n = 6), mice treated with bleomycin and SB 204741 at a concentration of 5 mg/kg/d (n = 6), and mice treated with bleomycin and imatinib at a concentration of 50 mg/kg/d (n = 6). Bars, 100 µm. (B) Dermal thickening upon challenge with bleomycin and treatment with terguride, cyproheptadine, SB 204741, or imatinib. (C) Collagen accumulation in lesional skin as analyzed with the SirCol collagen assay. (D) Myofibroblast counts after treatment of bleomycin-challenged mice with terguride, cyproheptadine, SB 204741, or imatinib. *, P < 0.05 compared with bleomycin-treated mice without antifibrotic treatment. The experiment was performed in two independent series. Error bars indicate SE.CC BY-NC-SA · PubMed Central
Figure 6. Mice lacking 5-HT2B are protected from bleomycin-induced dermal fibrosis. (A) Trichrome-stained tissue sections of 5-HT2B−/− and wild-type mice. Representative tissue sections are shown: 5-HT2B+/+ mice injected with NaCl intracutaneously, 5-HT2B−/− mice receiving intracutaneous injections of NaCl, 5-HT2B+/+ mice receiving intracutaneous injections of bleomycin, and 5-HT2B−/− mice injected with bleomycin (n = 8 each). Bars, 100 µm. (B) Dermal thickening in bleomycin-challenged 5-HT2B−/− and wild-type mice. (C) Myofibroblast number in 5-HT2B–deficient and wild-type mice upon bleomycin challenge. *, P < 0.05 compared with bleomycin-injected wild-type mice. The experiment was performed in two independent series. Error bars indicate SE.
Figure 6. Mice lacking 5-HT2B are protected from bleomycin-induced dermal fibrosis. (A) Trichrome-stained tissue sections of 5-HT2B−/− and wild-type mice. Representative tissue sections are shown: 5-HT2B+/+ mice injected with NaCl intracutaneously, 5-HT2B−/− mice receiving intracutaneous injections of NaCl, 5-HT2B+/+ mice receiving intracutaneous injections of bleomycin, and 5-HT2B−/− mice injected with bleomycin (n = 8 each). Bars, 100 µm. (B) Dermal thickening in bleomycin-challenged 5-HT2B−/− and wild-type mice. (C) Myofibroblast number in 5-HT2B–deficient and wild-type mice upon bleomycin challenge. *, P < 0.05 compared with bleomycin-injected wild-type mice. The experiment was performed in two independent series. Error bars indicate SE.CC BY-NC-SA · PubMed Central
Figure 7. Deficiency of 5-HT2B corrects the histological changes in Tsk-1 mice. (A) Representative sections of trichrome staining are shown: 5-HT2B+/+ mice without Tsk-1 allele (n = 5), 5-HT2B−/− mice without Tsk-1 allele (n = 8), 5-HT2B+/+/Tsk-1 mice (n = 5), and 5-HT2B−/−/Tsk-1 mice (n = 8). Vertical bars indicate the hypodermal thickness. Bars, 250 µm. (B) Hypodermal thickness in 5-HT2B–deficient Tsk-1 mice. (C) Collagen content in the skin of 5-HT2B−/−/Tsk-1 mice. (D) Myofibroblast counts in Tsk-1 mice after knockdown of 5-HT2B. *, P < 0.05 compared with 5-HT2B+/+/Tsk-1 mice. The measurements were performed twice. Error bars indicate SE.
Figure 7. Deficiency of 5-HT2B corrects the histological changes in Tsk-1 mice. (A) Representative sections of trichrome staining are shown: 5-HT2B+/+ mice without Tsk-1 allele (n = 5), 5-HT2B−/− mice without Tsk-1 allele (n = 8), 5-HT2B+/+/Tsk-1 mice (n = 5), and 5-HT2B−/−/Tsk-1 mice (n = 8). Vertical bars indicate the hypodermal thickness. Bars, 250 µm. (B) Hypodermal thickness in 5-HT2B–deficient Tsk-1 mice. (C) Collagen content in the skin of 5-HT2B−/−/Tsk-1 mice. (D) Myofibroblast counts in Tsk-1 mice after knockdown of 5-HT2B. *, P < 0.05 compared with 5-HT2B+/+/Tsk-1 mice. The measurements were performed twice. Error bars indicate SE.CC BY-NC-SA · PubMed Central
Figure 8. Mice lacking TPH1 are protected from bleomycin-induced dermal fibrosis. (A) Trichrome-stained tissue sections are shown: TPH1+/+ mice injected with NaCl intracutaneously (n = 7), TPH1−/− mice with intracutaneous injections of NaCl (n = 5), bleomycin-injected TPH1+/+ mice (n = 7), and TPH1−/− mice challenged with bleomycin (n = 5). Bars, 100 µm. (B) Dermal thickness in bleomycin-challenged TPH1-deficient mice. (C) Collagen protein content in bleomycin-challenged TPH1−/− mice as analyzed by hydroxyproline assay. (D) Changes in the number of α-SMA–positive myofibroblasts upon bleomycin challenge in TPH1-deficient mice. *, P < 0.05 compared with bleomycin-injected wild-type mice. The experiment was performed in two independent series. Error bars indicate SE.
Figure 8. Mice lacking TPH1 are protected from bleomycin-induced dermal fibrosis. (A) Trichrome-stained tissue sections are shown: TPH1+/+ mice injected with NaCl intracutaneously (n = 7), TPH1−/− mice with intracutaneous injections of NaCl (n = 5), bleomycin-injected TPH1+/+ mice (n = 7), and TPH1−/− mice challenged with bleomycin (n = 5). Bars, 100 µm. (B) Dermal thickness in bleomycin-challenged TPH1-deficient mice. (C) Collagen protein content in bleomycin-challenged TPH1−/− mice as analyzed by hydroxyproline assay. (D) Changes in the number of α-SMA–positive myofibroblasts upon bleomycin challenge in TPH1-deficient mice. *, P < 0.05 compared with bleomycin-injected wild-type mice. The experiment was performed in two independent series. Error bars indicate SE.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. von Werner, 1989, Therapy with terguride, Nichidoku-Iho., 33, 189

Cited by

See all 302

Metadata

Authors
Dees, C., Akhmetshina, A., Zerr, P., Reich, N., Palumbo, K., Horn, A., Jüngel, A., Beyer, C., Krönke, G., Zwerina, J., Reiter, R., Alenina, N., Maroteaux, L., Gay, S., Schett, G., Distler, O., & Distler, J. H. W.
Affiliations
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • University Hospital Zurich (CH)
  • ErgoNex Pharma GmbH, CH-9050 Appenzell, Switzerland 3
  • Max Delbrück Center (DE)
  • Inserm (FR)
Corresponding author
Distler, Jörg H.W.
Venue
Journal of Experimental Medicine
Published
2011-04-25
Volume
208
Issue
5
Pages
961-972
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2025287936
Cited by
266
References
63
Citations by year
2026: 3 · 2025: 14 · 2024: 11 · 2023: 11 · 2022: 13 · 2021: 22 · 2020: 22 · 2019: 14 · 2018: 22 · 2017: 12 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 21 · 2012: 37
FWCI
19.30
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
serotonin, platelets, 5-HT2B receptor, skin fibrosis, systemic sclerosis, extracellular matrix synthesis, fibroblasts, TGF-beta signaling, platelet activation, vascular injury, tissue remodeling, tryptophan hydroxylase 1, therapeutic target
MeSH terms
Animals, Blood Platelets, Disease Models, Animal, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Scleroderma, Systemic, Serotonin, Signal Transduction, Platelet Activation, Transforming Growth Factor beta, Mice, Knockout, Receptor, Serotonin, 5-HT2B, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.